Alector, Inc. (ALEC)
NASDAQ: ALEC · Real-Time Price · USD
1.760
+0.070 (4.14%)
At close: Jan 7, 2026, 4:00 PM EST
1.800
+0.040 (2.27%)
After-hours: Jan 7, 2026, 5:00 PM EST
Alector Employees
Alector had 238 employees as of December 31, 2024. The number of employees decreased by 6 or -2.46% compared to the previous year.
Employees
238
Change (1Y)
-6
Growth (1Y)
-2.46%
Revenue / Employee
$290,118
Profits / Employee
-$452,672
Market Cap
192.11M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 238 | -6 | -2.46% |
| Dec 31, 2023 | 244 | -29 | -10.62% |
| Dec 31, 2022 | 273 | 65 | 31.25% |
| Dec 31, 2021 | 208 | 37 | 21.64% |
| Dec 31, 2020 | 171 | 50 | 41.32% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ALEC News
- 26 days ago - Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer - GlobeNewsWire
- 4 weeks ago - Alector, Inc. (ALEC) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript - Seeking Alpha
- 5 weeks ago - Alector to Participate in the Bank of America CNS Therapeutics Conference - GlobeNewsWire
- 6 weeks ago - ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 2 months ago - Alector Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce - Benzinga
- 2 months ago - Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic - GlobeNewsWire
- 2 months ago - Alector shares plunge after dementia drug fails to slow disease progression - Reuters